Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 2/2009

01-04-2009 | PRECLINICAL STUDIES

Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer

Authors: Manon Buijs, Josephina A. Vossen, Jean-Francois H. Geschwind, Takayoshi Ishimori, James M. Engles, Obele Acha-Ngwodo, Richard L. Wahl, Mustafa Vali

Published in: Investigational New Drugs | Issue 2/2009

Login to get access

Summary

Purpose: To evaluate the anti-glycolytic effects of 3-BrPA on rats bearing RMT mammary tumors, by determining FDG uptake after intravenous administration of the therapeutic dose. Materials and Methods: Sixteen rats bearing RMT tumors were treated either with 15 mM 3-BrPA in 2.5 ml of PBS or with 2.5 ml of PBS. After treatment, all rats received FDG and were sacrificed 1 h later. Results: 3-BrPA treatment significantly decreased FDG uptake in tumors by 77% (p = 0.002). FDG uptake did not significantly decrease in normal tissues after treatment. Conclusion: Our study showed that 3-BrPA exhibits a strong anti-glycolytic effect on RMT cells implanted in rats.
Literature
1.
2.
Dumitrescu RG, Cotarla I (2005) Understanding breast cancer risk—where do we stand in 2005? J Cell Mol Med 9:208–221PubMedCrossRef
3.
Louwman MW, Vriezen M, van Beek MW et al (2007) Uncommon breast tumors in perspective: incidence, treatment and survival in The Netherlands. Int J Cancer 121:127–135PubMedCrossRef
4.
Elias D, Pietroantonio DD (2006) Surgery for liver metastases from breast cancer. HPB Oxf 8:97–99
5.
Perez EA (1999) Current management of metastatic breast cancer. Semin Oncol 26:1–10PubMed
6.
Anderson DM, Rolnick SJ, Jackson J, Amundson J, Asche SE, Loes LM (2007) Impact of chemotherapy in women with metastatic breast cancer diagnosed 1990–2003. Clin Breast Cancer 7:801–803PubMedCrossRef
7.
Rabbani SA, Mazar AP (2007) Evaluating distant metastases in breast cancer: from biology to outcomes. Cancer Metastasis Rev 26:663–674PubMedCrossRef
8.
Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181PubMedCrossRef
9.
Geschwind JF, Georgiades CS, Ko YH, Pedersen PL (2004) Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther 4:449–457PubMedCrossRef
10.
Isidoro A, Casado E, Redondo A et al (2005) Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 26:2095–2104PubMedCrossRef
11.
Shin SW, Han H, Choo SW et al (2006) Hepatic intra-arterial injection of 3-bromopyruvate in rabbit VX2 tumor. Acta Radiol 47:1036–1041PubMedCrossRef
12.
Vali M, Liapi E, Kowalski J et al (2007) Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol 18:95–101PubMedCrossRef
13.
Ko YH, Pedersen PL, Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173:83–91PubMedCrossRef
14.
Xu RH, Pelicano H, Zhou Y et al (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65:613–621PubMedCrossRef
15.
Kim W, Yoon JH, Jeong JM et al (2007) Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol Cancer Ther 6:2554–2562PubMedCrossRef
16.
Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL (2006) Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 33:254–262PubMedCrossRef
17.
Delbeke D (1999) Oncological applications of FDG PET imaging. J Nucl Med 40:1706–1715PubMed
18.
Ethier SP, Cundiff KC (1987) Importance of extended growth potential and growth factor independence on in vivo neoplastic potential of primary rat mammary carcinoma cells. Cancer Res 47:5316–5322PubMed
19.
Wahl RL, Henry CA, Ethier SP (1992) Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology 183:643–647PubMed
20.
Margolis DJ, Hoffman JM, Herfkens RJ, Jeffrey RB, Quon A, Gambhir SS (2007) Molecular imaging techniques in body imaging. Radiology 245:333–356PubMedCrossRef
21.
Avril N, Menzel M, Dose J et al (2001) Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 42:9–16PubMed
22.
Endo K, Oriuchi N, Higuchi T et al (2006) PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol 11:286–296PubMedCrossRef
23.
Pantaleo MA, Nannini M, Maleddu A et al (2008) Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev 34:103–121PubMedCrossRef
24.
Minn H, Kangas L, Knuutila V, Paul R, Sipila H (1991) Determination of 2-fluoro-2-deoxy-D-glucose uptake and ATP level for evaluating drug effects in neoplastic cells. Res Exp Med (Berl) 191:27–35CrossRef
25.
Yamada K, Brink I, Bisse E, Epting T, Engelhardt R (2005) Factors influencing [F-18] 2-fluoro-2-deoxy-D-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity. J Dermatol 32:316–334PubMed
26.
Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL (2002) Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62:3909–3913PubMed
Metadata
Title
Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer
Authors
Manon Buijs
Josephina A. Vossen
Jean-Francois H. Geschwind
Takayoshi Ishimori
James M. Engles
Obele Acha-Ngwodo
Richard L. Wahl
Mustafa Vali
Publication date
01-04-2009
Publisher
Springer US
Published in
Investigational New Drugs / Issue 2/2009
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-008-9145-0

Other articles of this Issue 2/2009

Investigational New Drugs 2/2009 Go to the issue

PHASE I STUDIES

Synthesis and antiproliferative activity of substituted diazaspiro hydantoins: a structure–activity relationship study

Phase II Studies

Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)

PRECLINICAL STUDIES

Suppressive effects of novel derivatives prepared from Aconitum alkaloids on tumor growth

SHORT REPORT

Bowel perforation in non-small cell lung cancer after bevacizumab therapy

PRECLINICAL STUDIES

In vitro cytotoxic activity of tri-n-butyltin(IV)lupinylsulfide hydrogen fumarate (IST-FS 35) and preliminary antitumor activity in vivo

PRECLINICAL STUDIES

Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R)

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits